Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% Net income of $93 million; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 Operating cash flow of

Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale RADNOR, Pa., July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Corey...

Achieves 2025 Greenhouse Gas Emission reduction goals two years ahead of schedule RADNOR, Pa., June 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced that Michael...